LAMP HUMAN CYP2C19 mutation KIT
| Format | References |
| 24 reactions | LC-CYP2C19-LP-24 |
INTENDED USE
The LAMP human CYP2C19 mutation KIT is an in vitro diagnostic test intended for
the qualitative detection of two different CYP2C19 alleles. This assay is dedicated to professional
use in diagnostic laboratory. The device is not for self-testing.
DISEASE INFORMATION
CYP2C19 enzyme plays a role in the processing or metabolizing of at least 10% of commonly prescribed
drugs, including clopidogrel, an antiplatelet drug. CYP2C19 enzyme converts clopidogrel (an inactive
prodrug) to its active form, which is necessary for the drug to function in the body. CYP2C19 is also
involved in the metabolism of antidepressant such as amiptriptyline, moclobemide, citalopram and
escitalopram. SNPs in this gene might cause several adverse events (cardiotoxicity, toxicity for the CNS,
hepatotoxicity) The two most common CYP2C19 gene polymorphism associated with clopidogrel resistance are
CYP2C19*2 and CYP2C19*3 , which result in the production of a nonfunctional (=loss of function) CYP2C19
enzyme that is unable to activate clopidogrel.
CYP2C19*2: 681 G>A (Prevalence ~15% among Caucasians)
CYP2C19*3 : 636 G>A (Prevalence <1% in Caucasians)
The SNP CYP2C19*17 806 C>T (allele frequency ~18% in Caucasians) is in development at LaCAR. This SNP increases the enzyme's ability to metabolize drugs (40% increase) such as the metabolism of Smephenytoin (anti-convulsant), omeprazole (proton pump inhibitor), and citalopram (antidepressant SSRI)